Core Insights - Gaxos.ai Inc. has launched Art-Gen.AI, an AI image and video creation platform aimed at simplifying professional-grade content creation for users globally [1][2] - The generative AI market is projected to reach hundreds of billions of dollars in annual revenue over the next decade, positioning Gaxos to capture significant market share through a subscription-based model [2][3] Company Overview - Gaxos.ai is focused on developing AI applications across high-growth sectors, including health, wellness, and gaming, aiming to redefine the human-AI relationship [5] - The company emphasizes long-term value creation for shareholders by empowering creators and enterprises with advanced content production capabilities [3] Product Features - Art-Gen.AI offers features such as instant image and video generation from text prompts, smart image transformation, one-click upscaling, dynamic video creation, and an AI prompt writer [7] - The platform includes style presets for various visual themes and a live creative gallery for user inspiration [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41620 GAXOS.AI INC. (Exact name of registrant as specified in its charter) Delaware 87-3288897 (State or other juris ...

Forward-Looking Statements All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "ex ...

Revenue and Expenses - For the three months ended March 31, 2025, the company generated revenues of $23,732, primarily from RNK Health, which provided non-clinical services totaling $22,552[120]. - Operating expenses for the same period increased by $371,569, or 35.6%, totaling $1,415,427 compared to $1,043,858 in the prior year[121]. - General and administrative expenses totaled $1,194,438, reflecting an increase of $332,909, or 38.7%, compared to $861,529 in the previous year[123]. - Research and development fees rose to $220,989, an increase of $38,660, or 21.2%, primarily due to costs associated with Gaxos Health[122]. Net Loss and Cash Flow - The net loss for the three months ended March 31, 2025, was $1,232,062, an increase of $319,917, or 35.1%, from $912,145 in the same period of 2024[130]. - The company reported a loss from operations of $1,391,695 for the three months ended March 31, 2025, an increase of $347,856, or 33.3%[128]. - For the three months ended March 31, 2025, the net cash used in operations was $1,297,485, primarily due to a net loss of $1,232,062[134]. - For the three months ended March 31, 2024, the net cash used in operations was $1,099,417, resulting from a net loss of $912,145[135]. Investments and Financing - For the three months ended March 31, 2025, net cash used in investing activities was $10,529,274, mainly from the purchase of short-term investments of $12,171,293[136]. - The company sold 1,449,277 common shares at $3.45 per share in December 2024, generating net proceeds of $4,449,055[132]. - For the three months ended March 31, 2024, net cash provided by financing activities was $3,037,382, following a private placement of common stock and warrants[139]. Future Outlook and Plans - The company expects to continue generating operating losses in the foreseeable future due to corporate overhead and research and development costs[133]. - The company believes existing working capital will be sufficient to meet operating needs for the next twelve months[133]. - The company plans to pursue research and development of products, requiring additional capital from third-party sources[140]. Company Initiatives - The company launched Gaxos Labs in September 2024, focusing on generative AI services for game developers and publishers[109]. - Gaxos Health, initiated in 2024, aims to provide AI-powered health optimization solutions, integrating biometric data with personalized wellness strategies[111]. Accounting and Compliance - The company did not have any off-balance sheet arrangements for the three months ended March 31, 2025 and 2024[141]. - The company intends to rely on exemptions under the JOBS Act until certain revenue or debt thresholds are met[146]. - The company does not expect the adoption of new accounting standards to have a material impact on its consolidated financial statements[142].

Core Insights - Gaxos.ai Inc. has received approval for its product Gaxos Labs for Game Developers and Publishers to be listed on Amazon Web Services (AWS) Marketplace, enhancing its market presence and distribution capabilities [1][2]. Group 1: Product and Market Impact - The listing on AWS Marketplace is a significant milestone in the company's go-to-market strategy, allowing for seamless deployment to millions of AWS customers across 245 countries and territories [2]. - The AWS Marketplace inclusion transforms Gaxos Labs from a standalone SaaS solution into a cloud-native, enterprise-grade service integrated into the AWS ecosystem, thereby expanding its global reach [3]. Group 2: Benefits of AWS Marketplace Inclusion - Key benefits include immediate exposure to all active AWS customers, the ability for AWS customers to use AWS Credits for payment, built-in AWS billing integration, global scalability with automated deployment capabilities, and qualification for co-selling with Amazon's global sales force [7].

Core Insights - Gaxos.ai Inc. has officially launched the AI-enabled Gaxos Health mobile application for iOS and Android, aimed at enhancing individual health outcomes through personalized technology [1][2] - The Gaxos Health app utilizes proprietary algorithms to provide goal-based wellness protocols, including nutrition, fitness, supplementation, and behavioral coaching [2][4] - The CEO of Gaxos, Vadim Mats, emphasized the potential of Gaxos Health in the multi-trillion-dollar health and wellness industry, aiming to deliver value to both users and shareholders [3] Company Overview - Gaxos Health's mission is to optimize human performance by offering customized health and wellness plans that integrate science and technology [4] - The app includes various packages such as biomarker testing, personalized nutrition plans, fitness routines, supplement plans, and live coaching [4][8] - Gaxos.ai Inc. is focused on redefining the human-AI relationship, with offerings that span health, wellness, and gaming [5] Application Features - The Gaxos Health app provides personalized nutrition plans based on macronutrient needs and meal quantity [8] - It creates exercise plans tailored to individual fitness levels and goals [8] - The app encourages the development of core habits like hydration, sleep, and sun exposure, along with habit and meal tracking features to support overall health [8]

Revenue and Financial Performance - In 2024, the company generated revenues of $4,027 from health coaching packages, a significant increase from $256 in 2023[223]. - The net loss for 2024 was $3,424,283, a decrease of $523,814, or 13.3%, compared to a net loss of $3,948,097 in 2023[233]. - The company reported a loss from operations of $3,703,605 in 2024, down from $4,015,285 in 2023, a decrease of $311,680, or 7.8%[231]. - For the year ended December 31, 2024, net cash used in operations was $3,280,397, primarily due to a net loss of $3,424,283[237]. - For the year ended December 31, 2023, net cash used in operations was $2,980,592, with a net loss of $3,948,097[238]. Expenses - Operating expenses decreased by $307,909, or 7.7%, from $4,015,541 in 2023 to $3,707,632 in 2024[224]. - Research and development expenses increased by $80,669, or 8.8%, from $915,818 in 2023 to $996,487 in 2024, primarily due to costs associated with Gaxos Health[225]. - General and administrative expenses totaled $2,711,145 in 2024, down from $3,047,360 in 2023, reflecting a decrease of $336,215[226]. - The company expects to continue generating operating losses in the foreseeable future due to corporate overhead and R&D costs[236]. Cash Flow and Financing - The company reported net cash provided by financing activities of $16,586,051 for the year ended December 31, 2024, mainly from common stock sales and warrant exercises[241]. - The company sold 1,449,277 common shares at $3.45 per share, generating net proceeds of $4,449,055 after fees[235]. - The company raised $3,600,656 from a securities purchase agreement on December 26, 2024, selling 1,346,669 shares at $3.00 each[235]. - Net cash provided by investing activities for the year ended December 31, 2024, was $67,735, resulting from short-term investment sales[239]. Initiatives and Subsidiaries - Gaxos Health, a new initiative, aims to provide AI-driven personalized wellness strategies, integrating biometric data and health goals[215]. - RNK Health, a subsidiary formed in September 2024, focuses on marketing health-related products, including GLP-1 medications[218]. - The company launched four proprietary games in 2023, enhancing user engagement through AI personalization and NFT minting[214]. Shareholder Actions - The company purchased and canceled 6,846 treasury shares for $19,602 at an average price of $2.86 per share in 2024[241]. - As of December 31, 2024, the company had a cash balance of $14,398,099 and working capital of $16,427,618[234]. Future Plans - The company plans to pursue research and development of new products, requiring additional capital from third-party sources[243]. - The company did not have any off-balance sheet arrangements for the years ended December 31, 2024, and 2023[244].

Core Insights - Gaxos.ai Inc. has acquired AI technology to enhance its content creation services, expanding the capabilities of Gaxos Labs and supporting broader AI development initiatives [1][2] - The acquisition introduces advanced AI solutions such as text-to-speech, image generation, video assembly, narration, styling, and script automation, creating new opportunities for users and enterprises [2] - CEO Vadim Mats emphasized that this acquisition strengthens the AI ecosystem of the company and accelerates the development of AI-powered content creation [3] Company Overview - Gaxos.ai Inc. is focused on redefining the human-AI relationship, with applications spanning health, wellness, and gaming, aiming to address issues related to health, longevity, and entertainment through AI solutions [4]

Core Viewpoint - Gaxos.ai Inc. has reincorporated from Delaware to Nevada, a move approved by both the board of directors and stockholders, with no impact on existing contracts or company operations [1][2][3]. Group 1: Reincorporation Details - The reincorporation was approved at the Annual Meeting of stockholders on December 27, 2024 [2]. - The company will continue to operate under the same stock symbol "GXAI" on the Nasdaq Capital Market, and no new stock certificates will be issued [4]. Group 2: Company Operations - The reincorporation does not affect any of the company's contracts with third parties, and all rights and obligations remain intact [3]. - There have been no changes to the Board of Directors, management, business, or operations as a result of the reincorporation [3]. Group 3: Company Overview - Gaxos.ai Inc. focuses on developing artificial intelligence applications in health, wellness, and gaming sectors, aiming to redefine the human-AI relationship [5].

Company Overview - Gaxos.ai Inc. is focused on developing artificial intelligence applications across various sectors, particularly in health, wellness, and gaming [3] - The company aims to redefine the human-AI relationship and is committed to addressing health, longevity, and entertainment through AI solutions [3] Upcoming Event - Gaxos will participate in the Sequire Investor Summit from January 21 to 23, 2025, in San Juan, Puerto Rico [1] - The CEO of Gaxos, Vadim Mats, expressed enthusiasm about presenting the company's initiatives to investors and other participants at the summit [2] - The Sequire Investor Summit is a significant event that will feature over 75 presenting companies and more than 500 investors, funds, family offices, and analysts [2]